Why This Matters
For the first time in Medicare's history, eligible beneficiaries can access GLP-1 weight-loss drugs through the federal program that insures more than 67 million Americans. The Medicare GLP-1 Bridge Program launched July 1, 2026, charging eligible Part D enrollees a flat $50 per month co-pay for certain GLP-1 medications prescribed for obesity.
That access is real, meaningful, and new. But it comes with a structural warning that is not being widely communicated to the beneficiaries beginning therapy: this program expires December 31, 2027. The longer-term initiative that was supposed to replace it — the BALANCE Model — has been delayed indefinitely by the Centers for Medicare and Medicaid Services. Congressional action would be required to make GLP-1 coverage for weight loss permanent in Medicare. No legislation is currently enacted that would accomplish that.
For patients beginning therapy through the Bridge, the question of what happens in January 2028 is not hypothetical. It is the central unanswered question of the largest new drug access program Medicare has launched in years.
What We Know So Far
Federal law prohibits Medicare Part D plans from covering medications prescribed for weight loss. That exclusion has long prevented Medicare from covering GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) for obesity, even as the same drugs are covered when prescribed for type 2 diabetes or cardiovascular disease.
The GLP-1 Bridge Program is a temporary payment demonstration operating outside the standard Part D benefit framework. Claims are processed through a centralized Medicare system rather than through individual Part D plan sponsors, at a negotiated price with manufacturers. Eligible Medicare Part D enrollees who meet clinical criteria for obesity or overweight with a related comorbidity, and who are not already using GLP-1 medications for another covered indication, may qualify.
The program was originally designed as a six-month bridge to the BALANCE Model, which was to have launched January 1, 2027. In April 2026, CMS announced that the BALANCE Model would be delayed indefinitely for Medicare Part D. CMS simultaneously extended the Bridge from a six-month program to an 18-month program, now running from July 2026 through December 2027, according to KFF analysis.
Where the Policy Gap Is Most Acute
The clinical population eligible for the Bridge is narrower than public discussion of GLP-1 access in Medicare often implies. An estimated 20 million Medicare beneficiaries could meet clinical criteria for weight-loss medications, according to some estimates, but KFF's narrower analysis estimates roughly 3.8 million Part D enrollees meet the Bridge's specific eligibility criteria after excluding people with diabetes, obstructive sleep apnea, metabolic liver disease, and existing GLP-1 users, all of whom may already access coverage through other channels.
At that enrollment scale, AJMC projects Medicare spending through December 2027 ranging from approximately $1.3 billion at 10% uptake to over $10 billion at 75% uptake. CMS has not published its own cost estimates for the demonstration period.
The $50 monthly co-pay, while substantially less than the list price of GLP-1 medications, may still be a barrier for low-income Medicare beneficiaries who rely on cost-sharing assistance. The Medicare Rights Center has noted that the $50 flat co-pay applies uniformly, without the income-adjusted cost-sharing protections that apply to Part D coverage for eligible low-income subsidy beneficiaries.
What Doctors and Experts Say
CMS has described the Bridge as a mechanism to gather utilization data that will inform future coverage decisions. The agency has given no concrete timeline for when or whether the BALANCE Model for Medicare Part D will be revived.
The AJMC analysis describes the situation plainly: patients face a potential coverage cliff at December 31, 2027, "with no confirmed permanent successor in place." Communication to beneficiaries about this limitation is inconsistent, and some patient advocates have raised concerns that people starting GLP-1 therapy through the Bridge may not understand that their access could be discontinued at the end of the demonstration period.
Obesity Medicine Association guidance to clinicians emphasizes that prescribers should inform patients of the temporary nature of the Bridge before initiating therapy. Clinical weight regain after stopping GLP-1 medications is well-documented, meaning a sudden coverage lapse carries real clinical consequences for patients who have begun to benefit from treatment.
What the Evidence Shows and What It Does Not
The GLP-1 Bridge Program is a demonstration project authorized under existing federal health program authority, not a new law. CMS has the authority to run demonstrations without congressional action, but making obesity drug coverage permanent in Medicare would require Congress to amend the Part D statute to remove the weight-loss exclusion.
Bills to do this, including the Treat and Reduce Obesity Act, have been introduced in multiple congressional sessions without enactment. Whether the Bridge program's utilization data will generate enough political momentum to produce legislation before the December 2027 deadline is an open policy question.
MedicalDaily Evidence Check
- Source: CMS GLP-1 Bridge Program guidance; KFF analysis updated May 11, 2026; AJMC analysis, July 2026; Medicare Rights Center, June 2026; Obesity Medicine Association, July 2026
- What it shows: Medicare GLP-1 Bridge launched July 1, 2026; $50/month co-pay; eligible Part D enrollees with obesity or overweight and comorbidities qualify; program expires December 31, 2027
- What it does not prove: That coverage will continue after 2027; BALANCE delay and absence of enacted legislation mean no permanent successor is in place
-
What readers should know: Beneficiaries should understand the temporary nature of the demonstration before starting therapy; clinical guidance for patients facing coverage uncertainty should come from their prescribing physician
Who Qualifies — and Who Does Not
To be eligible for the Medicare GLP-1 Bridge:
- The person must be enrolled in Medicare Part D
- They must meet the clinical criteria for obesity (BMI of 30 or higher) or overweight with at least one weight-related comorbidity, as specified in CMS program documentation
- They must not already be receiving GLP-1 medication coverage through another Medicare benefit for another indication (such as type 2 diabetes)
People who already have GLP-1 coverage through Part D for diabetes or cardiovascular disease are not affected by this program. The Bridge is specifically for people whose only indication is obesity or weight management, a category previously excluded from Part D coverage under federal law.
Symptoms and Warning Signs to Watch For
GLP-1 medications are generally well tolerated but carry a consistent side effect profile. Patients starting therapy through the Bridge should be aware of:
- Nausea, vomiting, diarrhea, or constipation, particularly during dose escalation
- Reduced appetite, which is the desired mechanism but can lead to nutritional deficiencies if not managed
- Rare but serious risks including pancreatitis, gallbladder problems, and kidney injury from dehydration
Anyone experiencing severe abdominal pain, persistent vomiting, or signs of dehydration should contact their physician promptly. GLP-1 medications should not be started or continued without medical supervision.
What You Can Do Now
- If you have Medicare Part D and think you may qualify for the Bridge, speak with your physician about whether you meet the clinical eligibility criteria and whether GLP-1 therapy is medically appropriate for your situation.
- Before starting therapy, ask your physician directly: what is the plan if coverage through the Bridge is discontinued at the end of 2027? Understand whether the medication would be accessible through another channel, at what cost, and what the clinical plan is if you need to stop.
- If you are a low-income Medicare beneficiary, ask whether any additional assistance programs may be available to help cover the $50 co-pay. Contact your State Health Insurance Assistance Program (SHIP) counselor for guidance on your specific situation.
-
Stay informed about legislative developments. If Congress acts to expand permanent Medicare coverage of GLP-1 drugs for obesity, the coverage picture after 2027 could change. Advocacy organizations including the
Obesity Action Coalition
track legislative developments and provide updates to patients.
Cost and Access: What Patients Should Know
The Bridge charges eligible Medicare beneficiaries a flat $50 per month co-pay for participating GLP-1 medications. This is substantially less than the $500 to $1,300 monthly list prices of most injectable GLP-1 drugs and considerably less than the $149 per month self-pay option for Foundayo (orforglipron), the oral GLP-1 approved in April 2026.
The co-pay applies to the approved drug at the dose prescribed. Specific drugs covered under the Bridge include certain FDA-approved GLP-1 medications for obesity; prescribers and pharmacies can confirm which products are eligible when processing claims through the Medicare central payment system.
Manufacturer patient assistance programs may be available for beneficiaries who face financial hardship, but eligibility criteria differ by manufacturer. Medicaid beneficiaries in states participating in the BALANCE Medicaid component, which is proceeding as planned through December 2031, may have separate coverage access not affected by the Medicare Bridge status.
What Happens Next
CMS has indicated no timeline for reinstating the BALANCE Medicare Part D component. The agency has stated it will use Bridge utilization data to inform future coverage decisions, but what specific data would trigger a BALANCE relaunch has not been specified.
The Treat and Reduce Obesity Act, which would permanently remove the statutory weight-loss drug exclusion from Medicare Part D, remains pending in Congress without passage as of this writing. Oral GLP-1 drugs, including Foundayo (orforglipron), are also expected to seek Medicare coverage in this evolving landscape, adding further complexity and fiscal pressure to the coverage question.
Both the Medicare Rights Center and KFF recommend that beneficiaries and their physicians discuss the temporary nature of the Bridge program explicitly before starting therapy.
The Bottom Line
Medicare's GLP-1 Bridge gives eligible beneficiaries meaningful access to weight-loss drugs for the first time in the program's history, at a $50 monthly co-pay, starting July 1, 2026. But the program expires December 31, 2027, and the longer-term BALANCE replacement has been indefinitely delayed. Congressional action is the only path to permanent coverage, and no legislation has been enacted. Patients beginning therapy through the Bridge should understand what they are entering before they start: a real but time-limited access window, followed by an unresolved policy question that will directly affect their ability to continue treatment.
